- Conditions
- Healthy Volunteers
- Interventions
- Cobicistat, Darunavir/Cobicistat, Rivaroxaban
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–31
of 31
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Gemcitabine, Nab-paclitaxel, PEGPH20
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
- Conditions
- Thrombosis
- Interventions
- Rivaroxaban, Acetylsalicylic Acid
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 8 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more
- Conditions
- Atrial Fibrillation, Percutaneous Coronary Intervention
- Interventions
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 86
- States / cities
- Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
- Conditions
- Prevention, Venous Thromboembolism
- Interventions
- Rivaroxaban (BAY59-7939), Enoxaparin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Denver, Colorado • Bay Pines, Florida + 2 more
- Conditions
- Healthy
- Interventions
- Ciraparantag, Placebo, Rivaroxaban
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (BAY59-7939), Enoxaparin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 10 more